⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
CONCORDBIO - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.9
| Stock Code | CONCORDBIO | Market Cap | 11,938 Cr. | Current Price | 1,141 ₹ | High / Low | 2,150 ₹ |
| Stock P/E | 37.6 | Book Value | 174 ₹ | Dividend Yield | 0.94 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,222 ₹ | DMA 200 | 1,443 ₹ |
| Chg in FII Hold | -0.45 % | Chg in DII Hold | 0.03 % | PAT Qtr | 70.2 Cr. | PAT Prev Qtr | 62.9 Cr. |
| RSI | 43.4 | MACD | -16.3 | Volume | 4,23,536 | Avg Vol 1Wk | 2,61,497 |
| Low price | 1,057 ₹ | High price | 2,150 ₹ | PEG Ratio | 1.40 | Debt to equity | 0.00 |
| 52w Index | 7.74 % | Qtr Profit Var | -5.20 % | EPS | 30.1 ₹ | Industry PE | 27.6 |
📊 Core Financials
- Revenue Growth: Moderate, PAT ₹70.2 Cr vs ₹62.9 Cr (QoQ growth but recent profit variation -5.20%)
- Profit Margins: Reasonable, EPS ₹30.1
- Debt Ratio: Debt-free (Debt-to-Equity 0.00)
- Cash Flows: Stable, supported by consistent profitability
- Return Metrics: ROCE 28.4%, ROE 21.4% — solid but not exceptional
💹 Valuation Indicators
- P/E Ratio: 37.6 (above industry PE of 27.6, slightly overvalued)
- P/B Ratio: ~6.6 (premium valuation)
- PEG Ratio: 1.40 (reasonable, growth moderately priced in)
- Intrinsic Value: Current price ₹1,141 is closer to lower band (₹1,057), offering cautious entry opportunity
🏢 Business Model & Competitive Advantage
- Pharmaceutical & biotech company with strong R&D focus
- Debt-free balance sheet provides financial flexibility
- Moderate dividend yield (0.94%) adds shareholder value
- Industry growth potential supports long-term demand
📈 Entry Zone & Long-Term Guidance
- Entry Zone: ₹1,080–₹1,150 range (near support levels)
- Long-Term Holding: Suitable for investors seeking exposure to biotech growth
- Risk: Valuation premium and recent profit decline may limit near-term upside
✅ Positive
- Debt-free company ensures strong financial stability
- Consistent PAT growth over quarters
- Solid ROCE and ROE metrics
⚠️ Limitation
- P/E ratio higher than industry average, indicating overvaluation
- Profit variation (-5.20%) shows earnings volatility
- Dividend yield is modest compared to peers
📰 Company Negative News
- Decline in FII holdings (-0.45%) shows reduced foreign investor interest
- Stock trading below DMA 50 & DMA 200, reflecting weak momentum
🌟 Company Positive News
- Quarterly PAT growth from ₹62.9 Cr to ₹70.2 Cr
- DII holdings increased slightly (+0.03%)
- Debt-free status enhances resilience
🏦 Industry
- Biotech & pharma sector with strong long-term demand
- Industry PE at 27.6, CONCORDBIO trades above this, showing premium valuation
- High R&D intensity creates growth opportunities but adds volatility
🔎 Conclusion
- CONCORDBIO is financially stable with debt-free operations and solid returns
- Valuation is premium compared to industry, limiting near-term upside
- Entry near ₹1,080–₹1,150 is favorable for long-term investors
- Best suited for investors with high risk tolerance and long-term horizon